Department of Brain Health News
The department of brain health is dedicated to advancing research, education, and clinical care to benefit brain health and the care and treatment of people with brain disorders across the lifespan. The faculty specializes in several areas that range from basic to clinical research in neurodegenerative disease and stroke.
Current Brain Health News
The top news stories starring university students and staff.
Data provided by UNLV researchers helped secure FDA approval for a new blood test to detect Alzheimer’s disease.
The top headlines featuring UNLV’s staff and students.
Report led by noted Alzheimer's researcher Dr. Jeffrey Cummings assesses status, trends associated with 182 active clinical trials worldwide.
UNLV research team says high blood sugar levels appear to weaken function in key part of brain, mimicking Alzheimer’s.
The 'Brain Health Frontiers: Tackling Alzheimer's Together' panel discussion highlighted the revolutionary research the Department of Brain Health is conducting to fight Alzheimer’s disease.
Brain Health In The News
Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias. This is a transformative, international study, but CNS is the only Las Vegas research site participating.
A study on Ozempic’s impacts on Alzheimer’s disease didn’t have the results scientists hoped for. We talk to UNLV’s Dr. Jeffrey Cummings on the research and what’s next. Also from UNLV: a look at how a “new” species of an ancient human ancestor can help shape our view on evolution. We end with a fun story on “Silver Belle”... the first tree from Nevada to serve as the U.S. Capitol Christmas Tree!
A study on Ozempic’s impacts on Alzheimer’s disease didn’t have the results scientists hoped for. We talk to UNLV’s Dr. Jeffrey Cummings on the research and what’s next. Also from UNLV: a look at how a “new” species of an ancient human ancestor can help shape our view on evolution. We end with a fun story on “Silver Belle”... the first tree from Nevada to serve as the U.S. Capitol Christmas Tree!
Over the past few years, scientists have learned that Ozempic and related drugs developed to treat Type 2 diabetes can improve the health of the liver, kidney and heart. Is it such a stretch to think they could also treat neurological disorders? Perhaps — at least when it comes to Alzheimer’s disease.
Alzheimer's patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to new data presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting.
Detailed results from the phase 3 EVOKE and EVOKE+ trials of the oral GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk) in early Alzheimer’s disease (AD) have been presented. The initial negative topline results announced last week by the company were met with disappointment in the AD research community, but the newly presented biomarker data offer some grounds for optimism and may point to a potential path forward.
